Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (NYSE: DGX) is a medical laboratories company focused on diagnostic testing and diagnostic information services, and its news flow reflects its role across the healthcare ecosystem. The company regularly issues updates on its financial reporting schedule, including announcements about quarterly and full-year results and related conference calls, which are of interest to investors tracking DGX stock and performance trends.
News about Quest Diagnostics also covers participation in major healthcare and investor conferences. For example, the company has announced presentations at events such as the J.P. Morgan Healthcare Conference and Citi’s Global Healthcare Conference, where its leadership discusses strategy, performance and market developments. These appearances provide insight into how the company views its position in the diagnostic testing and information services market.
Quest Diagnostics’ news includes information on collaborations and joint ventures that expand access to laboratory services. Announcements have highlighted a laboratory services joint venture with Corewell Health in Michigan, as well as the ongoing role of Sonora Quest Laboratories, an Arizona-based joint venture between Banner Health and Quest Diagnostics. Such items help readers understand how Quest Diagnostics partners with health systems to deliver regional laboratory services and hospital lab management solutions.
In addition, Quest Diagnostics reports on developments in specialized diagnostics through subsidiaries and collaborations. News has featured Haystack MRD, a minimal residual disease test developed by Haystack Oncology, a wholly owned subsidiary of Quest Diagnostics, including data presentations at scientific meetings and clinical research collaborations. Other coverage has described a strategic collaboration with Octave Bioscience to expand access to the Octave Multiple Sclerosis Disease Activity Test through Quest’s specimen-collection network.
Visitors to the DGX news page can review these types of updates to follow financial communications, strategic partnerships, scientific data presentations and corporate announcements that shape Quest Diagnostics’ activities in the medical laboratories sector.
Quest Diagnostics, a leading diagnostic information services company, will have its CEO speak at the 2024 Leerink Partners Healthcare Crossroads Conference. The event will cover the company's strategy, performance, and market trends, with a live webcast available for investors.
Quest Diagnostics and PathAI announced a collaboration to accelerate the adoption of digital and AI pathology innovations to improve cancer diagnosis. Quest will acquire select assets of PathAI Diagnostics to enhance its AI and digital capabilities. The transaction is expected to be completed in the second quarter of 2024. Additionally, Quest will license PathAI's AISight™ digital pathology image management system to support its pathology laboratories and customer sites in the U.S.
Quest Diagnostics has appointed Murali Balakumar as the Senior Vice President and Chief Information and Digital Officer, bringing 25 years of experience in technology strategy across healthcare, financial services, and transportation industries. As a digital transformation leader, Mr. Balakumar will oversee information technology, data informatics, and digital solutions for the company.
Quest Diagnostics collaborated with St. James Health to offer no-cost Blueprint for Wellness screenings during a Choose Healthy Life event at the Metropolitan Baptist Church in Newark. The event celebrated the expansion of the Willing Heart Community Care Center, supported by the Quest Diagnostics Foundation. The initiative aims to address social inequities in healthcare, employment, housing, and poverty. Quest provided 51 attendees with Blueprint for Wellness screenings, showcasing their commitment to health equity in underserved communities.
Quest Diagnostics and PathAI announced a collaboration to accelerate AI and digital pathology adoption in cancer diagnosis. Quest will acquire certain assets of PathAI Diagnostics to enhance its AI and digital capabilities. The transaction includes licensing agreements and is expected to close in Q2 2024. The partnership aims to improve cancer care quality and efficiency with cutting-edge technologies.
FAQ
What is the current stock price of Quest Diagnostics (DGX)?
What is the market cap of Quest Diagnostics (DGX)?
